DK1553950T3 - Terapeutisk behandling - Google Patents

Terapeutisk behandling

Info

Publication number: DK1553950T3
Authority: DK; Denmark
Prior art keywords: therapeutic treatment; therapeutic; treatment
Prior art date: 2002-10-12

Application number

DK03751038T

Other languages

English (en)

Inventor

Francis Thomas Boyle

Jon Owen Curwen

Neil James Gallagher

Ursula Joy Hancox

Andrew Mark Hughes

Donna Johnstone

Sian Tomiko Taylor

David William Tonge

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-12

Filing date

2003-10-07

Publication date

2007-10-15

2003-10-07 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2007-10-15 Application granted granted Critical

2007-10-15 Publication of DK1553950T3 publication Critical patent/DK1553950T3/da

Links

230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK03751038T 2002-10-12 2003-10-07 Terapeutisk behandling DK1553950T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0223854.1A GB0223854D0 (en)	2002-10-12	2002-10-12	Therapeutic treatment
PCT/GB2003/004347 WO2004035057A1 (en)	2002-10-12	2003-10-07	Therapeutic treatment

Publications (1)

Publication Number	Publication Date
DK1553950T3 true DK1553950T3 (da)	2007-10-15

Family

ID=9945876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03751038T DK1553950T3 (da)	2002-10-12	2003-10-07	Terapeutisk behandling

Country Status (29)

Country	Link
US (1)	US20060122180A1 (da)
EP (1)	EP1553950B1 (da)
JP (1)	JP2006510605A (da)
KR (1)	KR20050056238A (da)
CN (1)	CN100342853C (da)
AR (1)	AR041595A1 (da)
AT (1)	ATE369136T1 (da)
AU (1)	AU2003269259B2 (da)
BR (1)	BR0315140A (da)
CA (1)	CA2501959A1 (da)
CY (1)	CY1107605T1 (da)
DE (1)	DE60315490T2 (da)
DK (1)	DK1553950T3 (da)
ES (1)	ES2289316T3 (da)
GB (1)	GB0223854D0 (da)
IS (1)	IS2473B (da)
MX (1)	MXPA05003808A (da)
MY (1)	MY135441A (da)
NO (1)	NO20051658L (da)
NZ (1)	NZ539137A (da)
PL (1)	PL375584A1 (da)
PT (1)	PT1553950E (da)
RU (1)	RU2005114487A (da)
SA (1)	SA04240502B1 (da)
TW (1)	TW200412971A (da)
UA (1)	UA82492C2 (da)
UY (1)	UY28017A1 (da)
WO (1)	WO2004035057A1 (da)
ZA (1)	ZA200502874B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0218526D0 (en) *	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0219660D0 (en)	2002-08-23	2002-10-02	Astrazeneca Ab	Therapeutic use
WO2004100991A1 (en) *	2003-05-15	2004-11-25	Universite Catholique De Louvain	Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) *	2003-09-05	2003-10-08	Astrazeneca Ab	Therapeutic treatment
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
GB0425854D0 (en) *	2004-11-25	2004-12-29	Astrazeneca Ab	Therapeutic treatment
RU2412941C2 (ru) *	2006-03-13	2011-02-27	Инсайсив Фармасьютикалз, Инк.	Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида
KR20100099113A (ko) *	2007-10-12	2010-09-10	아스트라제네카 아베	만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
AU2010282744B2 (en)	2009-08-10	2014-08-28	Board Of Regents, The University Of Texas System	Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
CN116726183A (zh)	2015-08-03	2023-09-12	Enb治疗公司	用于治疗与etbr激活相关的癌症的组合物和方法
WO2019140324A1 (en)	2018-01-12	2019-07-18	Enb Therapeutics, Inc.	Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation
CN114423425A (zh) *	2019-07-17	2022-04-29	Enb治疗公司	通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
CN117255791B (zh)	2021-06-22	2026-06-19	亚克医药株式会社	化合物、内皮素a受体拮抗剂及医药组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5464853A (en) *	1993-05-20	1995-11-07	Immunopharmaceutics, Inc.	N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) *	1993-05-20	1996-05-07	Immunopharmaceutics, Inc.	N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
US6063911A (en) *	1993-12-01	2000-05-16	Marine Polymer Technologies, Inc.	Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
UA58494C2 (uk) *	1995-06-07	2003-08-15	Зенека Лімітед	Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) *	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
NZ508154A (en) *	1998-04-29	2003-07-25	Osi Pharm Inc	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6355678B1 (en) *	1998-06-29	2002-03-12	Parker Hughes Institute	Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) *	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
US20020055457A1 (en) *	2000-08-07	2002-05-09	Janus Todd J.	Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) *	2001-04-11	2003-05-15	Amitabh Singh	Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) *	2001-11-09	2003-05-22	Merck Patent Gmbh	Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

2002
- 2002-10-12 GB GBGB0223854.1A patent/GB0223854D0/en not_active Ceased
2003
- 2003-07-10 UA UAA200504329A patent/UA82492C2/uk unknown
- 2003-10-07 PT PT03751038T patent/PT1553950E/pt unknown
- 2003-10-07 NZ NZ539137A patent/NZ539137A/en not_active IP Right Cessation
- 2003-10-07 KR KR1020057006232A patent/KR20050056238A/ko not_active Ceased
- 2003-10-07 CN CNB2003801013102A patent/CN100342853C/zh not_active Expired - Fee Related
- 2003-10-07 DE DE60315490T patent/DE60315490T2/de not_active Expired - Lifetime
- 2003-10-07 PL PL03375584A patent/PL375584A1/xx not_active Application Discontinuation
- 2003-10-07 US US10/530,794 patent/US20060122180A1/en not_active Abandoned
- 2003-10-07 MX MXPA05003808A patent/MXPA05003808A/es active IP Right Grant
- 2003-10-07 CA CA002501959A patent/CA2501959A1/en not_active Abandoned
- 2003-10-07 ES ES03751038T patent/ES2289316T3/es not_active Expired - Lifetime
- 2003-10-07 EP EP03751038A patent/EP1553950B1/en not_active Expired - Lifetime
- 2003-10-07 DK DK03751038T patent/DK1553950T3/da active
- 2003-10-07 AU AU2003269259A patent/AU2003269259B2/en not_active Ceased
- 2003-10-07 JP JP2004544431A patent/JP2006510605A/ja active Pending
- 2003-10-07 WO PCT/GB2003/004347 patent/WO2004035057A1/en not_active Ceased
- 2003-10-07 RU RU2005114487/15A patent/RU2005114487A/ru unknown
- 2003-10-07 BR BR0315140-9A patent/BR0315140A/pt not_active IP Right Cessation
- 2003-10-07 AT AT03751038T patent/ATE369136T1/de active
- 2003-10-09 TW TW092128113A patent/TW200412971A/zh unknown
- 2003-10-10 MY MYPI20033877A patent/MY135441A/en unknown
- 2003-10-10 AR ARP030103717A patent/AR041595A1/es unknown
- 2003-10-13 UY UY28017A patent/UY28017A1/es not_active Application Discontinuation
2004
- 2004-02-18 SA SA04240502A patent/SA04240502B1/ar unknown
2005
- 2005-04-04 NO NO20051658A patent/NO20051658L/no not_active Application Discontinuation
- 2005-04-08 ZA ZA200502874A patent/ZA200502874B/en unknown
- 2005-04-26 IS IS7825A patent/IS2473B/is unknown
2007
- 2007-10-08 CY CY20071101275T patent/CY1107605T1/el unknown

Also Published As

Publication number	Publication date
EP1553950B1 (en)	2007-08-08
AU2003269259B2 (en)	2007-03-15
DE60315490T2 (de)	2008-05-08
KR20050056238A (ko)	2005-06-14
SA04240502B1 (ar)	2008-09-14
BR0315140A (pt)	2005-08-16
PL375584A1 (en)	2005-11-28
EP1553950A1 (en)	2005-07-20
JP2006510605A (ja)	2006-03-30
PT1553950E (pt)	2007-09-26
RU2005114487A (ru)	2006-02-10
WO2004035057A1 (en)	2004-04-29
UY28017A1 (es)	2004-04-30
IS7825A (is)	2005-04-26
ZA200502874B (en)	2006-02-22
MXPA05003808A (es)	2005-06-08
AU2003269259A1 (en)	2004-05-04
TW200412971A (en)	2004-08-01
UA82492C2 (uk)	2008-04-25
US20060122180A1 (en)	2006-06-08
HK1078784A1 (en)	2006-03-24
CN100342853C (zh)	2007-10-17
DE60315490D1 (de)	2007-09-20
CN1703224A (zh)	2005-11-30
MY135441A (en)	2008-04-30
ATE369136T1 (de)	2007-08-15
GB0223854D0 (en)	2002-11-20
CA2501959A1 (en)	2004-04-29
AR041595A1 (es)	2005-05-26
IS2473B (is)	2008-12-15
NZ539137A (en)	2008-01-31
ES2289316T3 (es)	2008-02-01
CY1107605T1 (el)	2013-03-13
NO20051658L (no)	2005-05-06

Publication	Publication Date	Title
NO20052914D0 (no)	2005-06-15	Terapeutiske forbindelser
DE60328797D1 (de)	2009-09-24	Blutbehandlungsgerät
GB0201850D0 (en)	2002-03-13	Therapeutic treatment
GB0216321D0 (en)	2002-08-21	Therapeutic treatment
GB0316912D0 (en)	2003-08-20	Therapeutic treatment
DE60311298D1 (de)	2007-03-08	Kopfhautbehandlung
GB0320806D0 (en)	2003-10-08	Therapeutic treatment
EP1570270A4 (en)	2010-09-22	THERAPEUTIC BIOKON JUGATE
GB0223367D0 (en)	2002-11-13	Therapeutic treatment
ATE389742T1 (de)	2008-04-15	Gewebebehandlungsmittel
DK1597171T3 (da)	2013-02-11	Terapeutisk mikroskum
ATA13602003A (de)	2005-04-15	Therapeutisches behandlungsgerät
IS7825A (is)	2005-04-26	Meðferðarfræðileg meðhöndlun
NO20050689L (no)	2005-03-21	Terapeutisk anvendelse
GB0210464D0 (en)	2002-06-12	Therapeutic treatment
GB0307863D0 (en)	2003-05-14	Therapeutic treatment
GB0329275D0 (en)	2004-01-21	Therapeutic treatment
GB0313772D0 (en)	2003-07-23	Therapeutic treatment
NO20022747D0 (no)	2002-06-07	Behandlingsstol
NO20042850L (no)	2004-08-26	Kreftbehandling
EP1511474A4 (en)	2008-02-20	Methods of Treatment
SE0203826D0 (sv)	2002-12-20	Therapeutic agents
SE0200450D0 (sv)	2002-02-13	Therapeutic agents
ITVE20020040A1 (it)	2004-05-16	Procedimento di trattamento delle pelli. -
FI20020356A0 (fi)	2002-02-22	Sauna